Loading...
Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
BACKGROUND: Alemtuzumab is approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab-related secondary autoimmune disorders (sAID) are common, with thyroid sAID being the most frequent, and fundamentally affect the risk-benefit ratio. Therefore, biomarkers indic...
Na minha lista:
| Udgivet i: | EBioMedicine |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6711888/ https://ncbi.nlm.nih.gov/pubmed/31371192 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.07.062 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|